UPLOAD Filing
Lyell Immunopharma, Inc.
Date: July 23, 2025 · CIK: 0001806952 · Accession: 0000000000-25-007760
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288769
Letter
Re: Lyell Immunopharma, Inc. Registration Statement on Form S-3 Filed July 18, 2025 File No. 333-288769 Dear Lynn Seely:
July 23, 2025
Lynn Seely President and Chief Executive Officer Lyell Immunopharma, Inc. 201 Haskins Way South San Francisco, CA 94080
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Thomas Greenberg
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> July 23, 2025 Lynn Seely President and Chief Executive Officer Lyell Immunopharma, Inc. 201 Haskins Way South San Francisco, CA 94080 Re: Lyell Immunopharma, Inc. Registration Statement on Form S-3 Filed July 18, 2025 File No. 333-288769 Dear Lynn Seely: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Thomas Greenberg </TEXT> </DOCUMENT>